Delivery of Nrf2 as therapy for protection against reactive oxygen species
US11053291B2 · kind B2 · utility
5Cited by
5References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 19, 2015 |
| Grant date | Jul 6, 2021 |
| Priority date | — |
| Expiry date | Feb 19, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/50
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides methods and compositions for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or inflammation, including ocular inflammation. In some embodiments, the methods comprise administering an expression vector that delivers a secretable and cell penetrating Nrf2 to a subject in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.